
Alessandra Reggiori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4520674/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly. Journal of Clinical Psychopharmacology, 2022, 42, 23-30.	1.4	4
2	Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance. Pharmacopsychiatry, 2020, 53, 209-219.	3.3	9
3	Aggressiveness and violence in psychiatric patients: a clinical or social paradigm?. CNS Spectrums, 2019, 24, 564-573.	1.2	9
4	Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation. Journal of Clinical Psychopharmacology, 2018, 38, 365-369.	1.4	9
5	Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics, 2018, 57, 1493-1528.	3.5	103
6	Gray matter volumes may predict the clinical response to paliperidone palmitate long-acting in acute psychosis: A pilot longitudinal neuroimaging study. Psychiatry Research - Neuroimaging, 2017, 261, 80-84.	1.8	9
7	Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disoder: A Prospective Observational Study. Therapeutic Drug Monitoring, 2017, 39, 441-445.	2.0	6
8	Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability. Pharmacopsychiatry, 2017, 50, 145-151.	3.3	10
9	Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation. Human Psychopharmacology, 2016, 31, 349-355.	1.5	5
10	"Long-acting―olanzapine in maintenance therapy of schizophrenia: A study with plasma levels. International Journal of Psychiatry in Clinical Practice, 2015, 19, 99-105.	2.4	15